Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

ConfirmMDx Genetic Test Identifies Prostate Cancer Aggressiveness

ConfirmMDx Genetic Test Identifies Prostate Cancer Aggressiveness

New data confirms that ConfirmMDx, an epigenetic assay, is able to accurately identify prostate cancer aggressiveness

Testosterone Replacement Therapy (TRT) May Promote Prostate Tumor Growth

Testosterone Replacement Therapy (TRT) May Promote Prostate Tumor ...

Testosterone replacement therapy (TRT) may promote prostate cancer tumor growth.

High Cholesterol Linked with Prostate Cancer Recurrence

High Cholesterol Linked with Prostate Cancer Recurrence

Findings suggest that normalization of blood fats may reduce risk of prostate cancer.